Slide 1: MST Financial Digital Health Forum Webinar
MST Financial Live Webinar and Q&A Digital Health Forum Webinar 13 June 2023 @ 11:30AM (AEST)
Slide 2: Important notice and disclaimer
Important notice and disclaimer this presentation, nor has it verified any of the contents of this presentation. You must consider your own financial situation, objectives and needs and conduct your own IMPORTANT NOTICE independent investigations, assessments and enquiries, including obtaining inves
Slide 3: Global Problem
Global Problem Coronary Artery Disease is a leading cause of death globally 126 $400 Every 13 One Nine million billion minutes third million people with heart disease costs Someone in of deaths globally CAD deaths significant the United States Australia dies of a are from heart per year2 heart disea
Slide 4: The culprit: Vulnerable Plaque
The culprit: Vulnerable Plaque Unstable soft plaque that ruptures 4% plaque burden = 5x increased risk of heart attack1 BUILD UP OF PLAQUE VULNERABLE PLAQUE IS DIFFICULT TO SEE AND RARELY REPORTED. 4 © ARTRYA © ARTRYA 1. Williams, M.C. et al. (2020) “Low-attenuation noncalcified plaque on coronary c
Slide 5: Current approaches fail to identify patients at risk of heart attack
Current approaches fail to identify patients at risk of heart attack Coronary Event Non-Invasive Testing Invasive Testing Treatment Patient Coronary CT Angiogram Invasive Blood Flow Test Statins Stents Chest pain • Current focus on calcium buildup and • Common procedure is invasive test, stenosis (n
Slide 6: Salix solution is unique reporting the real cause of death
Salix solution is unique reporting the real cause of death …within minutes In Development Overview of all key Non-invasive coronary findings assessment Salix Salix Overview of Coronary Coronary Vulnerable Plaque Anatomy Flow Review of blockages features SCA SCF Faster diagnosis Eliminates invasive O
Slide 7: Salix cuts overall scan-to-report time at the point-of-care
Salix cuts overall scan-to-report time at the point-of-care Salix Coronary Anatomy (SCA) < 15 minutes Radiologist / Manual Image Radiographer Referring Patient CCTA Scan Cardiologist clinician Post-Processing Workup Assess and report Current Workflow Up to 45 minutes per scan (for heavily diseased s
Slide 8: The product and its development
The product and its development Artrya’s product pipeline goes further & moves us towards predicting the patient at risk. CORONARY ARTERY SEVERITY OPTIMISED VULNERABLE ASSESSMENT FOR PROCEDURE PATIENT Blood flow FOR CAD assessment Vulnerable Patient Procedure & Plaque (artery and heart) treatment Pr
Slide 9: MST Financial Digital Health Forum Webinar Overview
MST Financial Market Digital Health Forum Webinar Overview
Slide 10: Capturing the CCTA Market Opportunity
Capturing the CCTA Market Opportunity 10–15% >4m of global CT scans will be 2 Artrya’s short term focus will 1 CCTA by 2025 (37.5m – be on accessible regions – 56m CCTA scans US, AUS, EU/UK globally) CCTA scans / year in 2021 Estimated US EU/UK Australia • 2.5m CCTA scans per year in 20213 • 1.7m CC
Slide 11: Focus areas & regulatory approval
Focus areas & regulatory approval FOCUS AREAS REGULATORY APPROVALS STATUS US FDA Australia Australian Market Entry New Zealand Research Market European CE Mark UK Conformity Assessment FDA strategy implementation Ongoing (Indicative timeframe) • Q-sub submission - May 2023 • Q-sub meeting completed
Slide 12: Business Model
Business Model SaaS business model… GLOBAL AVAILABILITY Charge a single flat fee Freemium Access a free version Pay-Go 24/7 Market entry for a limited period Scalability per image scanned. HIGH GROSS MARGIN Annuity stream for Value- Significant uplift in Subscription based revenue or decrease in Rep
Slide 13: Salix Coronary Anatomy – Brief Demo
Salix Coronary Anatomy – Brief Demo 13 © ARTRYA
Slide 14: MST Financial Thank You
MST Financial Thank You Digital Health Forum Webinar